HIV-1 INHIBITING PHARMACEUTICAL COMPOSITION CONTAINING AN ECKLONIA CAVA-DERIVED PHLOROGLUCINOL POLYMER COMPOUND
    1.
    发明申请
    HIV-1 INHIBITING PHARMACEUTICAL COMPOSITION CONTAINING AN ECKLONIA CAVA-DERIVED PHLOROGLUCINOL POLYMER COMPOUND 审中-公开
    含有ECKLONIA CAVA衍生的PHLOROGLUCINOL聚合物化合物的HIV-1抑制药物组合物

    公开(公告)号:US20130338218A1

    公开(公告)日:2013-12-19

    申请号:US13964687

    申请日:2013-08-12

    IPC分类号: C07D319/24

    摘要: The present invention relates to a HIV-1 inhibiting pharmaceutical composition containing, as an active ingredient, 6,6′-bieckol which is a phloroglucinol polymer compound separated from Ecklonia cava. The Ecklonia cava-derived 6,6′-bieckol according to the present invention inhibits HIV-1 induced cell fusion, the cell lysis effect, and the cytopathogenic effect including virus p24 antibody production, exhibits RT enzyme inhibition activity and HIV-1 infection inhibition activity, and shows no cytotoxicity at the concentration that almost perfectly inhibits HIC-1 replication.

    摘要翻译: 本发明涉及一种HIV-1抑制药物组合物,其含有作为活性成分的6,6'-双酚,其为从Ecklonia cava分离的间苯三酚聚合物化合物。 根据本发明的Ecklonia Cava衍生的6,6'-双卡洛酮抑制HIV-1诱导的细胞融合,细胞裂解作用和细胞病变效应,包括病毒p24抗体产生,表现出RT酶抑制活性和HIV-1感染抑制 活性,并且在几乎完全抑制HIC-1复制的浓度下不显示细胞毒性。